Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design
Jambon-Barbara C et al. Circulation, February 2026 (epub ahead of print) – open access publication
Link to full abstract